Literature DB >> 4005894

A clinically relevant model of heart failure: effects of ticlopidine.

A Nuttall, H J Smith, B E Loveday.   

Abstract

A clinically relevant model of heart failure has been developed in chronically instrumented mini-pigs by injecting Sephadex beads into the left main or circumflex coronary arteries under fluoroscopic control. In six control animals, left atrial pressure (LAP) increased from 10 +/- 2 to 19 +/- 2 mmHg (p less than 0.01) and remained elevated for 3 days. Heart rate increased by 26 beats X min-1 (p less than 0.05) and diastolic pressure fell after 24 h but recovered over the next 48 h. In six animals treated with ticlopidine (50 mg X kg-1 p.o.) for four days prior to embolisation, the acute haemodynamic changes were less in the first day but similar to control after 3 days. Infarct size was approximately 20% of the left ventricle in control animals and 9.5% in the treated group (p less than 0.01). ADP-induced platelet activity was reduced in the treated animals suggesting that coronary occlusion followed both physical occlusion by the beads and later development of platelet thrombi.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005894     DOI: 10.1093/cvr/19.4.187

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  3 in total

1.  The hemodynamic impact of diffuse myocardial ischemic lesions: an animal experimental model based on intracoronary microembolization.

Authors:  K Terp; W Y Kim; M Ulrich; J Frokiaer; U Baandrup; M Rehling; J P Bagger; J M Hasenkam
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

Review 2.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

3.  Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.

Authors:  E Udvary; J G Papp; A Végh
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.